Treatment of Vulvovaginitis

Vulvovaginal Candidiasis (VVC)

• The Centers for Disease Control and Prevention recommends short-course topical azole formulations (1-3 days) or single-dose oral fluconazole (150 mg) for uncomplicated VVC, with 80-90% success rates 1
• The Centers for Disease Control and Prevention suggests recommended topical treatments, including clotrimazole 1% cream for 7-14 days or clotrimazole vaginal tablets (100 mg for 7 days or 500 mg as single application), with a strength of evidence based on clinical trials 2, 1
• The Centers for Disease Control and Prevention recommends oral fluconazole 150 mg single oral dose as an alternative treatment for uncomplicated VVC, with a high success rate 1
• For severe VVC, the Centers for Disease Control and Prevention recommends extended topical azole therapy (7-14 days) or fluconazole 150 mg oral dose repeated after 72 hours, with a moderate strength of evidence 3, 2
• The Centers for Disease Control and Prevention defines recurrent VVC as 4 or more symptomatic episodes per year, affecting less than 5% of women, and recommends longer duration treatment (7-14 days topical or fluconazole 150 mg oral repeated after 3 days) for initial therapy, with a high strength of evidence 3
• For maintenance therapy of recurrent VVC, the Centers for Disease Control and Prevention recommends fluconazole 100-150 mg weekly or clotrimazole 500 mg vaginal suppositories weekly, with a moderate strength of evidence 3, 2
• The Centers for Disease Control and Prevention suggests that for non-albicans VVC, longer duration (7-14 days) with non-fluconazole azole drugs is recommended, with a low strength of evidence 4
• For persistent recurrence of non-albicans VVC, the Centers for Disease Control and Prevention recommends nystatin 100,000 units daily via vaginal suppositories, with a low strength of evidence 4
• In pregnancy, the Centers for Disease Control and Prevention recommends only topical azole therapies for 7 days, with a high strength of evidence 4
• For compromised hosts, the Centers for Disease Control and Prevention recommends extended 7-14 day treatment course, with a moderate strength of evidence 4

Follow-Up Considerations

• The Centers for Disease Control and Prevention recommends that patients should return only if symptoms persist or recur within 2 months, with a high strength of evidence 1
• For recurrent VVC, the Centers for Disease Control and Prevention suggests that vaginal cultures should be obtained to confirm diagnosis and identify unusual species, with a moderate strength of evidence 3
• The Centers for Disease Control and Prevention recommends that treatment of sex partners is generally not recommended for VVC but may be considered for recurrent cases, with a low strength of evidence 1

Common Pitfalls and Caveats

• The Centers for Disease Control and Prevention warns that inappropriate self-treatment with OTC products can delay proper diagnosis and treatment of other causes of vulvovaginitis, with a high strength of evidence 1
• The Centers for Disease Control and Prevention notes that identifying Candida without symptoms should not lead to treatment, as 10-20% of women normally harbor Candida, with a high strength of evidence 5
• The Centers for Disease Control and Prevention advises that azole creams and suppositories are oil-based and may weaken latex condoms and diaphragms, with a moderate strength of evidence 1

Itraconazole Dosing for Recurrent Vulvovaginal Candidiasis

Treatment Algorithm

• The Centers for Disease Control and Prevention (CDC) recommends itraconazole dosing as either 400 mg once monthly or 100 mg once daily for 6 months as maintenance therapy after achieving initial mycologic remission for recurrent vulvovaginal candidiasis (RVVC) 6, 7
• Initial induction therapy with longer duration initial treatment (7-14 days of topical azole therapy or fluconazole 150 mg repeated 3 days later) is critical before starting maintenance therapy to achieve mycologic remission 6

Critical Caveats

• The CDC guidelines emphasize that fluconazole is the first-line maintenance therapy and has demonstrated superior outcomes, improving quality of life in 96% of women with RVVC 8, 9
• Recurrence after stopping maintenance is common, with 30-40% of women having recurrent disease once any maintenance therapy is discontinued 6, 7, 8
• Vaginal cultures should be obtained in all RVVC cases to identify non-albicans species, as conventional azole therapies are less effective against these organisms 6, 7
• Itraconazole has clinically important interactions with various medications, including calcium channel antagonists, warfarin, and cyclosporine 6, 7
• Surveillance of recurrent isolates for development of resistance is prudent, especially given that antifungal activity is significantly reduced at vaginal pH 4 compared to laboratory testing at pH 7 6, 8, 9

Management of Complicated Vulvovaginal Candidiasis

Diagnostic Considerations

• The Centers for Disease Control and Prevention (CDC) recommends extended therapy for complicated VVC, which is classified as treatment failure after standard short-course therapy, requiring longer duration treatment (10-14 days) 10

Treatment Options

• The CDC recommends topical azole therapy for 7-14 days (such as terconazole 0.4% cream for 7 days, clotrimazole 1% cream for 7-14 days, or miconazole 2% cream for 7 days) as a first-line option for complicated VVC 10
• The CDC also recommends oral fluconazole 150 mg, repeated after 72 hours (two doses total), as a first-line option for complicated VVC, although this specific recommendation is not directly cited, the CDC guidelines are referenced 10

Special Considerations

• The CDC guidelines imply that oil-based vaginal creams and suppositories may weaken latex condoms and diaphragms, highlighting the need for alternative contraceptive methods 10

General Principles

• The CDC advises against treating asymptomatic colonization, as 10-20% of women normally harbor Candida species in the vagina without symptoms, and treatment is only indicated when symptoms are present with confirmed infection 10

Treatment of Recurrent Vulvovaginitis

Diagnosis and Treatment

• The Infectious Diseases Society of America recommends antifungal susceptibility testing at vaginal pH 4, as this reveals clinically significant resistance that standard testing misses, with MICs being 388-fold higher at vaginal pH 4 for certain species like C. glabrata 11
• Maintenance therapy with fluconazole 150 mg once weekly for 6 months after achieving initial mycologic remission improves quality of life in 96% of women, though recurrence after stopping maintenance occurs in 30-40% 11
• For non-albicans species, such as C. glabrata, 7-14 days of non-fluconazole azole therapy, like terconazole, is preferred due to its better activity against non-albicans species at vaginal pH 11
• Oteseconazole, a novel oral antifungal, showed remarkable efficacy in clinical trials with only 4% recurrence at 48 weeks compared to 52% with placebo 11
• Recurrence is common after stopping any maintenance therapy, with 30-40% for RVVC and up to 50% for BV within 1 year, making it essential to set realistic expectations 11
• Biofilm formation protects organisms from antimicrobials and contributes to persistence, highlighting the importance of extended therapy and biofilm-disrupting agents like boric acid 11

Management of Severe Vulvovaginal Candidiasis

Treatment Options

• Extended topical azole therapy (7–14 days) is recommended for severe VVC; options include clotrimazole 1 % cream 5 g intravaginally daily, miconazole 2 % cream 5 g daily for 7 days, terconazole 0.4 % cream 5 g daily for 7 days, or terconazole 0.8 % cream 5 g daily for 3 days.  12
• Oral fluconazole 150 mg given in two doses 72 hours apart provides significantly higher clinical cure rates (P = 0.015) and superior mycologic eradication compared with a single dose.  [13][14]
• CDC guidelines endorse the two‑dose fluconazole regimen as the standard practice for severe VVC.  [13][14]

Partner Management

• Routine treatment of sexual partners is not recommended because VVC is not sexually transmitted and partner therapy does not reduce recurrence.  [12][13]14
• Exception: male partners with symptomatic balanitis may receive topical antifungal therapy to relieve their own symptoms.  12

Diagnostic Considerations

• Confirm diagnosis before therapy by obtaining a vaginal wet‑mount preparation with 10 % potassium hydroxide to demonstrate yeast or hyphae.  15
• Measure vaginal pH; a pH < 4.5 supports VVC, whereas a higher pH suggests bacterial vaginosis or trichomoniasis.  15
• Obtain vaginal cultures when symptoms persist after treatment or in recurrent infection, as non‑albicans species require alternative management.  15

Special Populations

Pregnancy

• Use only topical azole therapy for 7 days; oral fluconazole is contraindicated.  [13][14]
• Acceptable topical agents in pregnancy include clotrimazole, miconazole, butoconazole, and terconazole.  12

Immunocompromised Hosts (e.g., uncontrolled diabetes, corticosteroid use, HIV)

• Provide an extended 7–14 day treatment course regardless of severity.  [13][14]
• Optimize modifiable risk factors such as glycemic control and minimizing corticosteroid exposure.  [13][14]
• HIV‑infected women receive the same regimens as non‑HIV women, though infections may be more severe.  [13][14]

Non‑albicans Candida Species

• First‑line therapy for C. glabrata or other non‑albicans species is a 7–14 day course of a non‑fluconazole azole (e.g., terconazole).  [13][14]
• Fluconazole is frequently ineffective against C. glabrata VVC.  15
• Recurrent infection with non‑albicans species may be treated with boric acid 600 mg vaginal capsules daily for 14 days (≈70 % cure rate).  [13][14]

Treatment Pitfalls

• Avoid short‑course (1–3 day) therapy for severe VVC as it leads to treatment failure.  [13][14]

Follow‑Up Recommendations

• Patients should return for evaluation only if symptoms persist or recur within 2 months after therapy.  12
• If symptoms persist, obtain vaginal cultures to identify non‑albicans species or azole resistance.  15
• Recurrent VVC (≥ 4 episodes per year) warrants investigation for predisposing factors and maintenance therapy with fluconazole 150 mg weekly for 6 months.  15

Clotrimazole Formulations and Dosing for Vulvovaginal Candidiasis

Available Formulations

• Clotrimazole is offered in intravaginal 1 % and 2 % cream preparations and in 100 mg and 500 mg tablet formulations, with treatment courses that can range from a single dose up to 14 days, allowing clinicians to match the regimen to infection severity. 16

Dosing Regimens for Uncomplicated VVC

• Intravaginal clotrimazole 1 % cream is applied as 5 g once daily for 7–14 days. 16
• Intravaginal clotrimazole 2 % cream is applied as 5 g once daily for 3 days. 16

Management of Non‑Albicans Candida Species

• For infections caused by Candida glabrata or other non‑albicans species, a 7–14‑day course of a non‑fluconazole azole (e.g., clotrimazole) is recommended because fluconazole frequently lacks efficacy against these organisms. 17
• Clotrimazole remains an appropriate topical option for treating infections due to non‑albicans Candida species. 17